Fig. 2From: The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)a Distribution of Recurrence Score results by (a) age, (b) tumor size, (c) tumor grade, and (d) Ki-67 expressionBack to article page